{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:19:47Z","timestamp":1782746387267,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11906-021-01137-6","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T04:02:20Z","timestamp":1617076940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Targets for Hypertension Drug Discovery"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-9300","authenticated-orcid":false,"given":"Lokesh Kumar","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishant","family":"Selokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezaree","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159\u2013219 Available from: https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/eht151.","journal-title":"Eur Heart J"},{"key":"1137_CR2","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Chow CK, Gupta R. Blood pressure control: a challenge to global health systems [Internet]. Lancet. Lancet Publishing Group; 2019 [cited 2021 Feb 1]. p. 613\u20135. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(19)31293-0. This paper is a commentary on increasing global burden of hypertension and challenges associated with this.","DOI":"10.1016\/S0140-6736(19)31293-0"},{"key":"1137_CR3","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Tocci G, Presta V, Ferri C, Redon J, Volpe M. Blood pressure targets achievement according to 2018 ESC\/ESH guidelines in three European excellence centers for hypertension. High Blood Press Cardiovasc Prev [Internet]. Springer International Publishing; 2020;27:51\u20139. Available from: https:\/\/doi.org\/10.1007\/s40292-020-00359-0. This is an important paper showing that proportions of treated uncontrolled hypertensive patients is substantially increased.","DOI":"10.1007\/s40292-020-00359-0"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40292-020-00420-y","volume":"27","author":"G Tocci","year":"2020","unstructured":"Tocci G, Presta V, Citoni B, Figliuzzi I, Bianchi F, Ferrucci A, et al. Blood pressure target achievement under monotherapy: a real-life appraisal. High Blood Press Cardiovasc Prev. 2020;27:587\u201396. Springer International Publishing Available from. https:\/\/doi.org\/10.1007\/s40292-020-00420-y.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","volume":"88","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Shi J, Liu ILA, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88:1099\u2013107 Elsevier Inc. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613005636.","journal-title":"Mayo Clin Proc"},{"key":"1137_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","volume":"73","author":"RM Carey","year":"2019","unstructured":"Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73:424\u201331 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.118.12191.","journal-title":"Hypertension"},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/hr.2010.183","volume":"34","author":"J Ceral","year":"2011","unstructured":"Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87\u201390 Nature Publishing Group. Available from: http:\/\/www.nature.com\/articles\/hr2010183.","journal-title":"Hypertens Res"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766\u201374 Available from: http:\/\/journals.lww.com\/00004872-201304000-00019.","journal-title":"J Hypertens"},{"key":"1137_CR9","doi-asserted-by":"crossref","unstructured":"Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ. Res. Lippincott Williams and Wilkins; 2015 [cited 2021 Mar 4]. p. 1074\u201395. Available from: http:\/\/circres.ahajournals.org","DOI":"10.1161\/CIRCRESAHA.116.303603"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.coi.2005.11.012","volume":"18","author":"LA O\u2019Neill","year":"2006","unstructured":"O\u2019Neill LA. How Toll-like receptors signal: what we know and what we don\u2019t know. Curr Opin Immunol. 2006;18:3\u20139 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791505002050.","journal-title":"Curr Opin Immunol"},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.4049\/jimmunol.166.3.2018","volume":"166","author":"E Faure","year":"2001","unstructured":"Faure E, Thomas L, Xu H, Medvedev AE, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-\u03b3 induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-\u03baB activation. J Immunol. 2001;166:2018\u201324 Available from: http:\/\/www.jimmunol.org\/lookup\/doi\/10.4049\/jimmunol.166.3.2018.","journal-title":"J Immunol"},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"H1069","DOI":"10.1152\/ajpheart.00143.2005","volume":"289","author":"X Yang","year":"2005","unstructured":"Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Circ Physiol. 2005;289:H1069\u201376 Available from: https:\/\/www.physiology.org\/doi\/10.1152\/ajpheart.00143.2005.","journal-title":"Am J Physiol Circ Physiol"},{"key":"1137_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0008-6363(02)00512-6","volume":"56","author":"S Zeuke","year":"2002","unstructured":"Zeuke S. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res. 2002;56:126\u201334 Available from: https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1016\/S0008-6363(02)00512-6.","journal-title":"Cardiovasc Res"},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/hr.2010.270","volume":"34","author":"R Ei\u00dfler","year":"2011","unstructured":"Ei\u00dfler R, Schmaderer C, Rusai K, K\u00fchne L, Sollinger D, Lahmer T, et al. Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res. 2011;34:551\u20138 Available from: http:\/\/www.nature.com\/articles\/hr2010270.","journal-title":"Hypertens Res"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1038\/s41598-017-06484-6","volume":"7","author":"S Pushpakumar","year":"2017","unstructured":"Pushpakumar S, Ren L, Kundu S, Gamon A, Tyagi SC, Sen U. Toll-like receptor 4 deficiency reduces oxidative stress and macrophage mediated inflammation in hypertensive kidney. Sci Rep. 2017;7:6349 Springer US Available from: http:\/\/www.nature.com\/articles\/s41598-017-06484-6.","journal-title":"Sci Rep"},{"key":"1137_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1042\/CS20110523","volume":"122","author":"GF Bomfim","year":"2012","unstructured":"Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535\u201343 Available from: https:\/\/portlandpress.com\/clinsci\/article\/122\/11\/535\/68943\/Tolllike-receptor-4-contributes-to-blood-pressure.","journal-title":"Clin Sci"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1111\/bph.13117","volume":"172","author":"R Hernanz","year":"2015","unstructured":"\u2022 Hernanz R, Mart\u00ednez-Revelles S, Palacios R, Mart\u00edn A, Cachofeiro V, Aguado A, et al. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol. 2015;172:3159\u201376 Available from: http:\/\/doi.wiley.com\/10.1111\/bph.13117. This paper provides evidences for the role of TLR4 in endothelial dysfunction in Ang II\u2013induced hypertension.","journal-title":"Br J Pharmacol"},{"key":"1137_CR18","first-page":"1","volume":"2013","author":"X Chen","year":"2013","unstructured":"Chen X, Shi X, Zhang X, Lei H, Long S, Su H, et al. Scutellarin Attenuates Hypertension-induced expression of brain Toll-like receptor 4\/nuclear factor kappa B. Mediat Inflamm. 2013;2013:1\u20139 Available from: https:\/\/www.hindawi.com\/journals\/mi\/2013\/432623\/.","journal-title":"Mediat Inflamm"},{"key":"1137_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.119.012195","volume":"8","author":"H Ichikawa","year":"2019","unstructured":"Ichikawa H, Shimada M, Narita M, Narita I, Kimura Y, Tanaka M, et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc. 2019;8:1\u201314 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.119.012195.","journal-title":"J Am Heart Assoc"},{"key":"1137_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/HYPERTENSIONAHA.111.169417","volume":"58","author":"JL McLarty","year":"2011","unstructured":"McLarty JL, Mel\u00e9ndez GC, Brower GL, Janicki JS, Levick SP. Tryptase\/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension. 2011;58:264\u201370 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.111.169417.","journal-title":"Hypertension"},{"key":"1137_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/mol.104.003103","volume":"67","author":"SF Steinberg","year":"2005","unstructured":"Steinberg SF. The cardiovascular actions of protease-activated rceptors. Mol Pharmacol: Am Soc Pharmacol Exp Ther. 2005;67:2\u201311 Available from: http:\/\/molpharm.aspetjournals.org\/lookup\/doi\/10.1124\/mol.104.003103.","journal-title":"Mol Pharmacol: Am Soc Pharmacol Exp Ther"},{"key":"1137_CR22","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.4049\/jimmunol.165.11.6504","volume":"165","author":"JR Lindner","year":"2000","unstructured":"Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, et al. Delayed Onset of inflammation in protease-activated receptor-2-deficient mice. J Immunol: Am Assoc Immunol. 2000;165:6504\u201310 Available from: http:\/\/www.jimmunol.org\/lookup\/doi\/10.4049\/jimmunol.165.11.6504.","journal-title":"J Immunol: Am Assoc Immunol"},{"key":"1137_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/89945","volume":"7","author":"N Vergnolle","year":"2001","unstructured":"Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 2001;7:821\u20136 Available from: http:\/\/www.nature.com\/articles\/nm0701_821.","journal-title":"Nat Med"},{"key":"1137_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1248\/bpb.b17-00987","volume":"41","author":"M Ando","year":"2018","unstructured":"\u2022 Ando M, Matsumoto T, Kobayashi S, Iguchi M, Taguchi K, Kobayashi T. Impairment of protease-activated receptor 2-induced relaxation of aortas of aged spontaneously hypertensive rat. Biol Pharm Bull. 2018;41:815\u20139 Available from: https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/5\/41_b17-00987\/_article. Results of this study suggested role of PAR-2 in hypertension.","journal-title":"Biol Pharm Bull"},{"key":"1137_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2016.03.094","volume":"473","author":"R-Q He","year":"2016","unstructured":"He R-Q, Tang X-F, Zhang B-L, Li X-D, Hong M-N, Chen Q-Z, et al. Protease-activated receptor 1 and 2 contribute to angiotensin II-induced activation of adventitial fibroblasts from rat aorta. Biochem Biophys Res Commun. 2016;473:517\u201323 Elsevier Ltd. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16304053.","journal-title":"Biochem Biophys Res Commun"},{"key":"1137_CR26","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.bbamcr.2016.01.003","volume":"1863","author":"L Xu","year":"2016","unstructured":"Xu L, Brink M. mTOR, cardiomyocytes and inflammation in cardiac hypertrophy. Biochim Biophys Acta, Mol Cell Res. 2016;1863:1894\u2013903 Elsevier B.V. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488916000069.","journal-title":"Biochim Biophys Acta, Mol Cell Res"},{"key":"1137_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in growth, metabolism, and disease. Cell. 2017;168:960\u201376 Elsevier Inc. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867417301824.","journal-title":"Cell"},{"key":"1137_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1172\/JCI73935","volume":"125","author":"CE Gleason","year":"2015","unstructured":"Gleason CE, Frindt G, Cheng C-J, Ng M, Kidwai A, Rashmi P, et al. mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity. J Clin Invest. 2015;125:117\u201328 Available from: http:\/\/www.jci.org\/articles\/view\/73935.","journal-title":"J Clin Invest"},{"key":"1137_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown EJ, Albers MW, Bum Shin T, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex. Nature. 1994;369:756\u20138 Available from: http:\/\/www.nature.com\/articles\/369756a0.","journal-title":"Nature"},{"key":"1137_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.2.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815\u201322 Available from: http:\/\/www.jbc.org\/lookup\/doi\/10.1074\/jbc.270.2.815.","journal-title":"J Biol Chem"},{"key":"1137_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867406001085.","journal-title":"Cell."},{"key":"1137_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cmet.2010.05.001","volume":"11","author":"P Kapahi","year":"2010","unstructured":"Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW-L, Thomas EL, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 2010;11:453\u201365 Elsevier Ltd; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413110001531.","journal-title":"Cell Metab"},{"key":"1137_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393 Elsevier; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867412003510.","journal-title":"Cell"},{"key":"1137_CR34","first-page":"1713","volume":"126","author":"M Laplante","year":"2013","unstructured":"Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013;126:1713\u20139 Available from: http:\/\/jcs.biologists.org\/cgi\/doi\/10.1242\/jcs.125773.","journal-title":"J Cell Sci"},{"key":"1137_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature11861","volume":"493","author":"SC Johnson","year":"2013","unstructured":"Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493:338\u201345 Available from: http:\/\/www.nature.com\/articles\/nature11861.","journal-title":"Nature"},{"key":"1137_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","volume":"78","author":"DM Sabatini","year":"1994","unstructured":"Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35\u201343 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0092867494905703.","journal-title":"Cell."},{"key":"1137_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.117.09456","volume":"70","author":"V Kumar","year":"2017","unstructured":"Kumar V, Wollner C, Kurth T, Bukowy JD, Cowley AW. Inhibition of mammalian target of rapamycin complex 1 attenuates salt-induced hypertension and kidney injury in Dahl salt-sensitive rats. Hypertension. 2017;70:813\u201321 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.117.09456.","journal-title":"Hypertension"},{"key":"1137_CR38","first-page":"813","volume":"38","author":"W Wang","year":"2015","unstructured":"Wang W, Wang H, Geng Q-X, Wang H-T, Miao W, Cheng B, et al. Augmentation of autophagy by atorvastatin via Akt\/mTOR pathway in spontaneously hypertensive rats. Hypertens Res [Internet]. Nat Publ Group. 2015;38:813\u201320 Available from: http:\/\/www.nature.com\/articles\/hr201585.","journal-title":"Nat Publ Group"},{"key":"1137_CR39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41401-019-0272-2","volume":"40","author":"Y Li","year":"2019","unstructured":"Li Y, Yang L, Dong L, Yang Z, Zhang J, Zhang S, et al. Crosstalk between the Akt\/mTORC1 and NF-\u03baB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs. Acta Pharmacol Sin. 2019;40:1322\u201333 Springer US; Available from: http:\/\/www.nature.com\/articles\/s41401-019-0272-2.","journal-title":"Acta Pharmacol Sin"},{"key":"1137_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.118.12378","volume":"73","author":"V Kumar","year":"2019","unstructured":"\u2022 Kumar V, Evans LC, Kurth T, Yang C, Wollner C, Nasci V, et al. Therapeutic suppression of mTOR (mammalian target of rapamycin) signaling prevents and reverses salt-induced hypertension and kidney injury in Dahl salt-sensitive rats. Hypertension. 2019;73:630\u20139 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.118.12378. The data from this paper reveals the role of mTOR and its pathway components for sodium balance and arterial BP regulation.","journal-title":"Hypertension"},{"key":"1137_CR41","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1210\/jc.2010-0042","volume":"95","author":"K Bozaoglu","year":"2010","unstructured":"Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95:2476\u201385 Endocrine Society; Available from: https:\/\/academic.oup.com\/jcem\/article\/95\/5\/2476\/2597606.","journal-title":"J Clin Endocrinol Metab"},{"key":"1137_CR42","doi-asserted-by":"crossref","unstructured":"Chu SH, Lee MK, Ahn KY, Im J-A, Park MS, Lee D-C, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. Ryffel B, editor. PLoS One [Internet]. 2012;7:e34710. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0034710","DOI":"10.1371\/journal.pone.0034710"},{"key":"1137_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2310\/JIM.0b013e3181ec5db2","volume":"58","author":"Y Mengliu","year":"2010","unstructured":"Mengliu Y, Gangyi Y, Jing D, Ying L, Haihong Z, Hua L, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. BMJ Publishing Group. 2010;58:883\u20136.","journal-title":"J Investig Med"},{"key":"1137_CR44","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/ATVBAHA.113.301476","volume":"33","author":"SW Watts","year":"2013","unstructured":"Watts SW, Dorrance AM, Penfold ME, Rourke JL, Sinal CJ, Seitz B, et al. Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol. 2013;33:1320\u20138 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.113.301476.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1137_CR45","doi-asserted-by":"publisher","first-page":"H1017","DOI":"10.1152\/ajpheart.00820.2014","volume":"309","author":"H Kunimoto","year":"2015","unstructured":"Kunimoto H, Kazama K, Takai M, Oda M, Okada M, Yamawaki H. Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure. Am J Physiol Circ Physiol. 2015;309:H1017\u201328 Available from: https:\/\/www.physiology.org\/doi\/10.1152\/ajpheart.00820.2014.","journal-title":"Am J Physiol Circ Physiol"},{"key":"1137_CR46","first-page":"1327","volume":"11","author":"J Wen","year":"2019","unstructured":"Wen J, Wang J, Guo L, Cai W, Wu Y, Chen W, et al. Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats. Am J Transl Res. 2019;11:1327\u201342 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30972165.","journal-title":"Am J Transl Res"},{"key":"1137_CR47","first-page":"3096","volume":"9","author":"C Weng","year":"2017","unstructured":"Weng C, Shen Z, Li X, Jiang W, Peng L, Yuan H, et al. Effects of chemerin\/CMKLR1 in obesity-induced hypertension and potential mechanism. Am J Transl Res. 2017;9:3096\u2013104 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28670396.","journal-title":"Am J Transl Res"},{"key":"1137_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.116.004421","volume":"5","author":"AJ Kennedy","year":"2016","unstructured":"\u2022 Kennedy AJ, Yang P, Read C, Kuc RE, Yang L, Taylor EJA, et al. Chemerin elicits potent constrictor actions via chemokine-like receptor 1 (CMKLR1), not G-protein-coupled receptor 1 (GPR1), in human and rat vasculature. J Am Heart Assoc. 2016;5:1\u201315 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.004421. This paper provides important finding that C9 chemerin increases contraction and pulmonary vascular resistance in arteries with increased BP.","journal-title":"J Am Heart Assoc"},{"key":"1137_CR49","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou M-X, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471\u20136 Academic Press Inc.; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X9899489X.","journal-title":"Biochem Biophys Res Commun"},{"key":"1137_CR50","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1161\/ATVBAHA.110.219980","volume":"31","author":"SM Chandra","year":"2011","unstructured":"Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus PV, et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011;31:814\u201320 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.110.219980.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1137_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.regpep.2005.09.032","volume":"133","author":"JP Goetze","year":"2006","unstructured":"Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, et al. Apelin: A new plasma marker of cardiopulmonary disease. Regul Pept. 2006;133:134\u20138 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016701150500234X.","journal-title":"Regul Pept"},{"key":"1137_CR52","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1113\/JP274178","volume":"595","author":"PR Griffiths","year":"2017","unstructured":"Griffiths PR, Lolait SJ, Harris LE, Paton JFR, O\u2019Carroll A-M. Vasopressin V1a receptors mediate the hypertensive effects of [Pyr 1 ]apelin-13 in the rat rostral ventrolateral medulla. J Physiol. 2017;595:3303\u201318 Available from: http:\/\/doi.wiley.com\/10.1113\/JP274178.","journal-title":"J Physiol"},{"key":"1137_CR53","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/JOE-13-0227","volume":"219","author":"A-M O\u2019Carroll","year":"2013","unstructured":"O\u2019Carroll A-M, Lolait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol. 2013;219:R13\u201335 Available from: https:\/\/joe.bioscientifica.com\/view\/journals\/joe\/219\/1\/R13.xml.","journal-title":"J Endocrinol"},{"key":"1137_CR54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0306-4522(02)00192-6","volume":"113","author":"A Reaux","year":"2002","unstructured":"Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience. 2002;113:653\u201362 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452202001926.","journal-title":"Neuroscience."},{"key":"1137_CR55","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1046\/j.1365-2826.2003.01044.x","volume":"15","author":"A-M O\u2019Carroll","year":"2003","unstructured":"O\u2019Carroll A-M, Lolait SJ. Regulation of rat APJ receptor messenger ribonucleic acid expression in magnocellular neurones of the paraventricular and supraopric nuclei by osmotic stimuli. J Neuroendocrinol. 2003;15:661\u20136 Available from: http:\/\/doi.wiley.com\/10.1046\/j.1365-2826.2003.01044.x.","journal-title":"J Neuroendocrinol"},{"key":"1137_CR56","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","volume":"36","author":"P Yang","year":"2015","unstructured":"Yang P, Maguire JJ, Davenport AP. Apelin, Elabela\/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36:560\u20137 Elsevier Ltd; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614715001170.","journal-title":"Trends Pharmacol Sci"},{"key":"1137_CR57","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/bph.14603","volume":"176","author":"P Yang","year":"2019","unstructured":"\u2022 Yang P, Read C, Kuc RE, Nyimanu D, Williams TL, Crosby A, et al. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019;176:1206\u201321 Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/bph.14603This paper suggest the role of apelin receptor on pulmonary hypertension and proposed that G protein-based agonism of the apelin receptor has a beneficial effect in PAH.","journal-title":"Br J Pharmacol"},{"key":"1137_CR58","doi-asserted-by":"crossref","unstructured":"Wang C, Liu X, Kong D, Qin X, Li Y, Teng X, et al. Apelin as a novel drug for treating preeclampsia. Exp Ther Med. 2017:5917\u201323 Available from: http:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.5304.","DOI":"10.3892\/etm.2017.5304"},{"key":"1137_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00424-012-1166-z","volume":"464","author":"JM Simard","year":"2012","unstructured":"Simard JM, Woo SK, Gerzanich V. Transient receptor potential melastatin 4 and cell death. Pflugers Arch - Eur J Physiol. 2012;464:573\u201382 Available from: http:\/\/link.springer.com\/10.1007\/s00424-012-1166-z.","journal-title":"Pflugers Arch - Eur J Physiol"},{"key":"1137_CR60","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.bcp.2012.06.021","volume":"84","author":"H Abriel","year":"2012","unstructured":"Abriel H, Syam N, Sottas V, Amarouch MY, Rougier J-S. TRPM4 channels in the cardiovascular system: physiology, pathophysiology, and pharmacology. Biochem Pharmacol. 2012;84:873\u201381 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295212004194.","journal-title":"Biochem Pharmacol"},{"key":"1137_CR61","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/cvr\/cvr135","volume":"91","author":"A Becerra","year":"2011","unstructured":"Becerra A, Echeverr\u00eda C, Varela D, Sarmiento D, Armis\u00e9n R, Nu\u00f1ez-Villena F, et al. Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. Cardiovasc Res. 2011;91:677\u201384 Available from: https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1093\/cvr\/cvr135.","journal-title":"Cardiovasc Res"},{"key":"1137_CR62","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1159\/000459695","volume":"41","author":"X-Q Ding","year":"2017","unstructured":"\u2022 Ding X-Q, Ban T, Liu Z-Y, Lou J, Tang L-L, Wang J-X, et al. Transient receptor potential melastatin 4 (TRPM4) contributes to high salt diet-mediated early-stage endothelial injury. Cell Physiol Biochem. 2017;41:835\u201348 Available from: https:\/\/www.karger.com\/Article\/FullText\/459695This paper provide evidences that TRPM4 is associated with high salt diet-mediated early-stage endothelial injury.","journal-title":"Cell Physiol Biochem"},{"key":"1137_CR63","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nature719","volume":"416","author":"DD McKemy","year":"2002","unstructured":"McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 2002;416:52\u20138 Available from: http:\/\/www.nature.com\/articles\/nature719.","journal-title":"Nature"},{"key":"1137_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pharmthera.2004.11.008","volume":"106","author":"J Calixto","year":"2005","unstructured":"Calixto J, Kassuya C, Andre E, Ferreira J. Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. Pharmacol Ther. 2005;106:179\u2013208 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804002049.","journal-title":"Pharmacol Ther"},{"key":"1137_CR65","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0092-8674(02)00652-9","volume":"108","author":"AM Peier","year":"2002","unstructured":"Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. A TRP channel that senses cold stimuli and menthol. Cell. 2002;108:705\u201315 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867402006529.","journal-title":"Cell"},{"key":"1137_CR66","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1172\/JCI41348","volume":"120","author":"I Mathar","year":"2010","unstructured":"Mathar I, Vennekens R, Meissner M, Kees F, Van der Mieren G, Camacho Londo\u00f1o JE, et al. Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice. J Clin Invest. 2010;120:3267\u201379 Available from: http:\/\/www.jci.org\/articles\/view\/41348.","journal-title":"J Clin Invest"},{"key":"1137_CR67","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.3892\/mmr.2017.6158","volume":"15","author":"F Huang","year":"2017","unstructured":"Huang F, Ni M, Zhang J-M, Li D-J, Shen F-M. TRPM8 downregulation by angiotensin II in vascular smooth muscle cells is involved in hypertension. Mol Med Rep. 2017;15:1900\u20138 Available from: https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.6158.","journal-title":"Mol Med Rep"},{"key":"1137_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.117.005495","volume":"6","author":"S Xiong","year":"2017","unstructured":"\u2022 Xiong S, Wang B, Lin S, Zhang H, Li Y, Wei X, et al. Activation of transient receptor potential melastatin subtype 8 attenuates cold-induced hypertension through ameliorating vascular mitochondrial dysfunction. J Am Heart Assoc. 2017;6:1\u201318 Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.005495The results of this study suggested that TRPM 8 activation attenuated cold-induced hypertension in rats.","journal-title":"J Am Heart Assoc"},{"key":"1137_CR69","unstructured":"Effects and safety of menthol on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients - full text view - ClinicalTrials.gov [Internet]. [cited 2021 Feb 1]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01408446?term=trpm&cond=Hypertension&draw=2&rank=1"},{"key":"1137_CR70","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.bjp.0704924","volume":"137","author":"JJ Maguire","year":"2002","unstructured":"Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol. 2002;137:579\u201388 Wiley-Blackwell. Available from: http:\/\/doi.wiley.com\/10.1038\/sj.bjp.0704924.","journal-title":"Br J Pharmacol"},{"key":"1137_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9146870","volume":"2016","author":"F Wu","year":"2016","unstructured":"Wu F, Chen G, Zhang A, Yu Y, Fan M, Tang C. Renal urotensin II system plays roles in the regulation of blood pressure in Dahl salt-resistant rat. Int J Hypertens. 2016;2016:1\u201311 Available from: https:\/\/www.hindawi.com\/journals\/ijhy\/2016\/9146870\/.","journal-title":"Int J Hypertens"},{"key":"1137_CR72","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.peptides.2005.10.004","volume":"27","author":"J Disa","year":"2006","unstructured":"Disa J, Floyd LE, Edwards RM, Douglas SA, Aiyar NV. Identification and characterization of binding sites for human urotensin-II in Sprague\u2013Dawley rat renal medulla using quantitative receptor autoradiography. Peptides. 2006;27:1532\u20137 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978105004730.","journal-title":"Peptides"},{"key":"1137_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/FJC.0000000000000618","volume":"73","author":"M Nishi","year":"2019","unstructured":"\u2022 Nishi M, Yonesu K, Tagawa H, Kato M, Marumoto S, Nagayama T. A novel and highly potent urotensin II receptor antagonist inhibits urotensin II\u2013induced pressure response in mice. J Cardiovasc Pharmacol. 2019;73:15\u201321 Available from: http:\/\/journals.lww.com\/00005344-201901000-00003. This study provides evidences that urotensin II receptor can be target for hypertension therapy and urotensin II receptor antagonist inhibited urotensin II\u2013induced pressure response.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1137_CR74","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.intimp.2016.09.002","volume":"40","author":"JH Lee","year":"2016","unstructured":"Lee JH, Park BK, Oh K, Yi KY, Lim CJ, Seo HW, et al. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. Int Immunopharmacol. 2016;40:196\u2013202 Elsevier B.V. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576916303770.","journal-title":"Int Immunopharmacol"},{"key":"1137_CR75","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1097\/01.hjh.0000420462.48113.d0","volume":"30","author":"P Chan","year":"2012","unstructured":"Chan P, Hong H-J, Cheng T-H. 945 Tanshinone IIA reduces urotensin II signaling and compromised migration in cultured vascular smooth muscle cells. J Hypertens. 2012;30:e273 Available from: http:\/\/journals.lww.com\/00004872-201209001-00871.","journal-title":"J Hypertens"},{"key":"1137_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6534512","volume":"2020","author":"S Yao","year":"2020","unstructured":"Yao S, Su C, Wu S-H, Hu D-J, Liu X. Aliskiren improved the endothelial repair capacity of endothelial progenitor cells from patients with hypertension via the Tie2\/PI3k\/Akt\/eNOS signalling pathway. Cardiol Res Pract. 2020;2020:1\u201311 Available from: https:\/\/www.hindawi.com\/journals\/crp\/2020\/6534512\/.","journal-title":"Cardiol Res Pract"},{"key":"1137_CR77","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cvr\/cvn048","volume":"78","author":"J-S Lee","year":"2008","unstructured":"Lee J-S, Song S-H, Kim J-M, Shin I-S, Kim KL, Suh Y-L, et al. Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res. 2008;78:572\u201380 Available from: https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1093\/cvr\/cvn048.","journal-title":"Cardiovasc Res"},{"key":"1137_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000112432","volume":"75","author":"A Yamamoto","year":"2008","unstructured":"Yamamoto A, Takahashi H, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, et al. Downregulation of angiopoietin-1 and Tie2 in chronic hypoxic pulmonary hypertension. Respiration. 2008;75:328\u201338 Available from: https:\/\/www.karger.com\/Article\/FullText\/112432.","journal-title":"Respiration."},{"key":"1137_CR79","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1084\/jem.20090389","volume":"206","author":"L Kugathasan","year":"2009","unstructured":"Kugathasan L, Ray JB, Deng Y, Rezaei E, Dumont DJ, Stewart DJ. The angiopietin-1\u2013Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice. J Exp Med. 2009;206:2221\u201334 Available from: https:\/\/rupress.org\/jem\/article\/206\/10\/2221\/46076\/The-angiopietin1Tie2-pathway-prevents-rather-than.","journal-title":"J Exp Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-021-01137-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:05:56Z","timestamp":1675134356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-021-01137-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s11906-021-01137-6","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"18 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"19"}}